Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Authors:
- Anita MangiaAMAnita Mangia
- Concetta SaponaroCSConcetta Saponaro
- Alessandro VaghegginiAVAlessandro Vagheggini
- Giuseppina OpintoGOGiuseppina Opinto
- Matteo CentonzeMCMatteo Centonze
- Chiara VicentiCVChiara Vicenti
- Ondina PopescuOPOndina Popescu
- Maria PastenaMPMaria Pastena
- Francesco GiottaFGFrancesco Giotta
- Nicola SilvestrisNicola Silvestris
Open Access
Abstract
Tumor-infiltrating lymphocytes (TILs) are a valuable indicator of the immune microenvironment that plays the central role in new anticancer drugs. TILs have a strong prognostic role in triple negative breast cancer (TNBC). Little is known about the interaction with the androgen receptor (AR) and forkhead box A1 (FOXA1). We analyzed the relationships between TIL levels, AR, and FOXA1 expression and their clinical significance in TNBC patients. Further, we investigated their interaction with other biomarkers like programmed cell death ligand-1 (PD-L1), breast cancer type 1 susceptibility protein (BRCA1), poly (ADP-Ribose) polymerase 1 (PARP1), and Na+/H+ exchanger regulatory factor 1 (NHERF1). The expression of the proteins was evaluated by immunohistochemistry in 124 TNBC samples. TILs were performed adhering to International TILs Working Group 2014 criteria. Cox proportional hazards models were also used to identify risk factors associated with poor prognosis. Multivariate analysis identified TILs as independent prognostic factor of disease free survival (DFS; p = 0.045). A Kaplan–Meyer analysis revealed that the patients with high TILs had a better DFS compared to patients with low TILs (p = 0.037), and the phenotypes TILs−/AR+ and TILs−/FOXA1− had a worse DFS (p = 0.032, p = 0.001 respectively). AR was associated with FOXA1 expression (p = 0.007), and the tumors FOXA1+ presented low levels of TILs (p = 0.028). A poor DFS was observed for AR+/FOXA1+ tumors compared to other TNBCs (p = 0.0117). Low TILs score was associated with poor patients’ survival, and TILs level in combination with AR or FOXA1 expression affected patient’s clinical outcome. In addition, AR+/FOXA1+ phenotype identified a specific subgroup of TNBC patients with poor prognosis. These data may suggest new ways of therapeutic intervention to support current treatments.Keywords
All Related Versions
This publication has 57 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Behavior of seeds and soil in the mechanism of metastasis: A deeper understandingCancer Science, 2012
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerCancer Cell, 2011
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1The EMBO Journal, 2011
- FOXA1 is an independent prognostic marker for ER-positive breast cancerBreast Cancer Research and Treatment, 2011
- FOXA1 is a key determinant of estrogen receptor function and endocrine responseNature Genetics, 2010
- Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Research and Treatment, 2009
- Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosisJournal of Clinical Pathology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1Cell, 2005